We updated the design of this site on September 25th. Learn more.
Show more
ClinicalTrials.gov Menu

Study of BMS-275183 in Patients With Pre-treated Non-small Cell Lung Cancer

This study has been terminated.
ClinicalTrials.gov Identifier:
First Posted: December 22, 2004
Last Update Posted: March 2, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Bristol-Myers Squibb
The purpose of this clinical research study is to learn if BMS-275183 can shrink or slow the growth of the cancer in subjects with non-small cell lung cancer (NSCLC). The safety of this treatment will also be studied.

Condition Intervention Phase
Non-small Cell Lung Cancer Drug: BMS-275183 Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Primary Purpose: Treatment
Official Title: A Randomized, Two-Cohort Phase II Study of Two Doses of BMS-275183 Given on a Weekly Schedule in Patients With Pre-Treated Non-Small Cell Lung Cancer

Resource links provided by NLM:

Further study details as provided by Bristol-Myers Squibb:

Primary Completion Date: March 2006 (Final data collection date for primary outcome measure)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Advanced or metastatic pretreated NSCLC
  • Measurable disease
  • Adequate hematologic, hepatic and renal functions
  • ECOG Performance Status of 0-2

Exclusion Criteria:

  • Inability to swallow capsules
  • Recent significant cardiovascular disease
  • Woman who are pregnant or breastfeeding
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00099879

United States, California
Local Institution
Sacramento, California, United States
United States, Connecticut
Local Institution
New Haven, Connecticut, United States
United States, Georgia
Local Institution
Atlanta, Georgia, United States
United States, Illinois
Local Institution
Maywood, Illinois, United States
United States, Michigan
Local Institution
Detroit, Michigan, United States
United States, Pennsylvania
Local Institution
Pittsburgh, Pennsylvania, United States
United States, Tennessee
Local Institution
Nashville, Tennessee, United States
Local Institution
Brussels, Belgium
Local Institution
Leuven, Belgium
Local Institution
Besancon, Cedex, France
Local Institution
Saint-Herblain, Cedex, France
Local Institution
Belfort, France
Local Institution
Parma, Italy
Local Institution
Roma, Italy
Local Institution
Amsterdam, Netherlands
Local Insitution
Groningen, Netherlands
Local Institution
Barcelona, Spain
Local Institution
Madrid, Spain
United Kingdom
Local Institution
Shefield, Yorkshire, United Kingdom
Local Institution
Manchester, United Kingdom
Sponsors and Collaborators
Bristol-Myers Squibb
  More Information

Additional Information:
ClinicalTrials.gov Identifier: NCT00099879     History of Changes
Other Study ID Numbers: CA165-020
First Submitted: December 21, 2004
First Posted: December 22, 2004
Last Update Posted: March 2, 2010
Last Verified: August 2007

Additional relevant MeSH terms:
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Diseases
Carcinoma, Bronchogenic
Bronchial Neoplasms